Pentavere is a Patient Identification Company that has built a best in class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration.
Pentavere and DARWEN™ AI have received significant acclaim from
major global pharmaceutical companies and healthcare leaders:
"Pentavere allows us to query our lung cancer data to give us an accurate snapshot of current clinical practice for advanced lung cancer patients."
"We are thrilled to have the opportunity to collaborate with Pentavere to leverage their AI technology within the field of rare diseases."
“Darwen enables the automation of data abstraction from unstructured hospital electronic medical records and may eliminate the need for manual chart review.”
“Pentavere has been an incredible partner in helping us unlock medical insights buried in free-text. Thank you Pentavere for helping us get that competitive edge with access to digestible insights."
“Thanks to Pentavere's innovative AI technology, the dismal scenario for rare disease patients could soon change. We are so proud and excited to have the opportunity to work with Pentavere’s AI and apply it to help rare diseases in Canada.”
“In a world drowning in data but thirsting for knowledge, Pentavere has cast a light on ways to alleviate this challenge. Companies like Pentavere will bring healthcare into the 21st century.”
Publications & Validation
"Pentavere created an automated, longitudinal, prospective data and analytics platform for breast cancer at a regional cancer center. This platform combines principles of data warehousing with NLP to provide the integrated, timely, meaningful, high-quality, and actionable data required to establish a learning health system."
“By comparing overlapping datasets, the strengths and weaknesses of each study design and extraction methodology were identified. This process demonstrated the effectiveness of artificial intelligence (DARWEN™) for extracting accurate patient-level clinicodemographic and mutation status data from EHRs”
This program offers a pathway to use data that already exists to intervene and set patients on the standard of care treatment pathway
Pentavere nominated for the Prix Galien Award two years in a row as best digital health start-up
“We are thrilled to have the opportunity to collaborate with Pentavere to leverage their AI technology within the field of rare diseases”